Filippo Benedetti

PhD student in Vienna, fascinated by Antibody Engineering 🧬, immuno-oncology 💉 and sports ⚽🏐🏀

[Filippo Benedetti @FilippBenedetti]

Check out our latest paper 🤩
Super thankful to everyone involved!
This also means new tweetorial🧵
https://t.co/WY7Vu5tVE7
⬇️⬇️ 1/n

[Filippo Benedetti @FilippBenedetti]

@GMFranceschini Lui e´ un boss

[Charlotte Zajc @ZajcCharlotte]

To the CAR T community-have you ever wondered why there are different affinities around for FMC63 - CD19? We unravelled this mysterium and determined the actual affinity range with different methods in our current paper- just published: https://t.co/s8XLAn5JzV Shares are welcome!

[Jason Sheltzer @JSheltzer]

New from my lab: we show that a clinical-stage oncology drug from Eli Lilly is mischaracterized, and its true anti-cancer target is EGFR.

We also show how in vitro drug assays can be misleading - cellular+genetic methods are needed to determine drug MOAs.

[Tae Seok Moon @Moon_Synth_Bio]

Wow, #Engineering #longevity @ScienceMagazine
https://t.co/krYqOwSDfF

[David R. Liu @davidrliu]

Today we report in @ScienceMagazine a one-time base editing treatment for Spinal Muscular Atrophy (SMA), the leading genetic cause of infant mortality worldwide, affecting ~1 in 10,000 births. https://t.co/oLp8VN0Iiw
PDF: https://t.co/JoKm9BxW89
1/17

[Björn Schumacher @schumacherbj]

Our DREAM paper is out: We found the first master regulator of DNA repair capacities! Read and re-tweet now: The DREAM complex functions as conserved master regulator of somatic DNA repair capacities, @CECAD_ @UKKoeln @UniCologne
https://t.co/rVMe4rAxaf

[Joazeiro Lab @LabJoazeiro]

How cool is that? New paper @Nature, E3 #ubiquitin ligases keep on giving
#Proteindegraders #PROTACs
https://t.co/KEATySnN7q

[Michael Dustin @MichaelLDustin]

T cells that received telomeres from antigen presenting cells provide durable protection from infection. Congratulations @lanna_alessio !
https://t.co/mj69nXZSF0

[Adrian Liston @LabListon]

@jennie_clough @HsiehElena @JossyGarciaP Arsene Mekinian using low-dose #IL2 on 18 patients with >5 unexplained #miscarriages. During a single fertility cycle, 10 patients became #pregnant and 4 gave live birth. 40% successful #pregnancy huge improvement for patients with >5 previous miscarriages! Hope for #infertility

[Paras Sharma @paras_biotech]

Clinical trials success rate by disease area (2010-2020)

**Look at Hem rate of success from Ph2-Ph3: 48%
while Oncology is at 25%

https://t.co/eGa0u9S3Mq

[Filippo Benedetti @FilippBenedetti]

Amazing teamwork! Thanks @merckgroup for the opportunity

[Merck @merckgroup]

Team Immuno-oncology is next on our #InnovationCup stage at our headquarters in Darmstadt. Six students from across the world presenting a project they worked on since Sunday this week.
@FilippBenedetti @diy_immuno
#science #technology

[Alex Chu @alexechu_]

my first paper! we used an old(?) hypothesis about IL-2 to get better affinity/specificity while *only* designing for stability. Also, no library screening needed :)

https://t.co/4qLpxJdrJp

[Ronen Segev @ronen_segev]

I am excited to share a new study led by Shachar Givon & @MatanSamina w/ Ohad Ben Shahar: Goldfish can learn to navigate a small robotic vehicle on land. We trained goldfish to drive a wheeled platform that reacts to the fish’s movement (https://t.co/ZR59Hu9sib).

[Filippo Benedetti @FilippBenedetti]

Love it!

[Emma J Chory @chorye]

Best way to ring in the new year! @erika_alden_d and I are excited to share our story on high-throughput continuous evolution, available now in @naturemethods. We've added a ton to the story since the preprint, and hope you'll check it out! thread 1/n... https://t.co/e76mfVIlNN

[Shi Yan @mryanshi]

Online lecture by Carolyn Bertozzi "Therapeutic Opportunities in Glycoscience"
#glycotime @CarolynBertozzi @oeaw
Time: 23.11.2021 at 17:00 (Central European Time)
Link: https://t.co/WChSyknoMg

[Filippo Benedetti @FilippBenedetti]

And this should be it! Stay tuned for bispecific-related research 👨‍🔬

[Filippo Benedetti @FilippBenedetti]

Check out our latest paper 🤩
Super thankful to everyone involved!
This also means new tweetorial🧵
https://t.co/WY7Vu5tVE7
⬇️⬇️ 1/n

[Filippo Benedetti @FilippBenedetti]

So we can conclude that the new molecule is a potent anti-HER2 agent able to:
- Induce HER2 internalization
- Inhibit cellular proliferation
- Cause cellular apoptosis 12/n